Low Dose Regimens of BNT162b2 mRNA Vaccine Exceed SARS-Cov-2 Correlate of Protection Estimates for Symptomatic Infection, in those 19-55 Years of Age
Graham Jurgens
doi: https://doi.org/10.1101/2021.03.06.21253058
Graham Jurgens
MD, HBSc (Microbiology and Immunology)
Posted March 11, 2021.
Low Dose Regimens of BNT162b2 mRNA Vaccine Exceed SARS-Cov-2 Correlate of Protection Estimates for Symptomatic Infection, in those 19-55 Years of Age
Graham Jurgens
medRxiv 2021.03.06.21253058; doi: https://doi.org/10.1101/2021.03.06.21253058
Subject Area
Subject Areas
- Addiction Medicine (317)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2318)
- Dermatology (205)
- Emergency Medicine (373)
- Epidemiology (11653)
- Forensic Medicine (10)
- Gastroenterology (687)
- Genetic and Genomic Medicine (3656)
- Geriatric Medicine (344)
- Health Economics (625)
- Health Informatics (2340)
- Health Policy (922)
- Hematology (337)
- HIV/AIDS (765)
- Medical Education (362)
- Medical Ethics (102)
- Nephrology (394)
- Neurology (3407)
- Nursing (193)
- Nutrition (512)
- Oncology (1787)
- Ophthalmology (529)
- Orthopedics (212)
- Otolaryngology (284)
- Pain Medicine (227)
- Palliative Medicine (66)
- Pathology (442)
- Pediatrics (1014)
- Primary Care Research (411)
- Public and Global Health (6046)
- Radiology and Imaging (1243)
- Respiratory Medicine (816)
- Rheumatology (373)
- Sports Medicine (319)
- Surgery (391)
- Toxicology (50)
- Transplantation (171)
- Urology (144)